Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal duration of first-line bevacizumab with carboplatin + paclitaxel in ovarian cancer
2011-001015-32Phase 3Completed
- Sponsor
- AGO Research
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoint: Progression-free survival. Started Jun 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2011-001015-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001015-32.